Anthem Biosciences Ltd. (ANTHEM) — key facts
NSE-listed · Healthcare. Data as of 11 Nov 2026 (IST) from InvestSights.
Last close: ₹959 (+1.77% day change)
Key ratios
- P/E ratio
- 90.9
- P/B ratio
- 12.1
- ROE (%)
- 19.45
- ROCE (%)
- 22.55
- Debt/Equity
- 0.02
- Dividend yield (%)
- 0
- Market cap (₹ Cr)
- 54,042.34
Forensic checks
Piotroski F-Score: 6/9 · Altman Z-Score: 18.04 · Beneish M-Score: -0
InvestSights quality score
68/100 — Above Average (descriptive data-driven composite; not a recommendation)
Management guidance track record
- Revenue growth: guided 15–16%, delivered 15.17% (FY26) — met guidance
- EBITDA margin: guided 40%, delivered 43.4% (FY26) — exceeded guidance
Latest earnings call (Q2 FY27)
AI summary: The central signal was that Q2 represented a meaningful operating recovery after a slow Q1, but management still needs strong execution through Q3 and Q4 to meet its stated ambition of double-digit FY27 growth. Q2 revenue from operations reached ₹594 crore, while EBITDA was ₹330 crore at a 50.6% margin, including other income of ₹59 crore. Management attributed the margin…
Full analysis on InvestSights
InvestSights is an analytics platform and is not SEBI-registered as a Research Analyst or Investment Adviser. All figures are educational, descriptive data — not investment advice. Consult a SEBI-registered adviser before investing.